Enovis CORP
No SEC Form 4 filings for $ENOV in the last 30 days.
See all $ENOV insider activity →UBS reduced its price target for Enovis Corp (NYSE:ENOV) to $44 from $51, citing the impact of its recent acquisition and seasonality. The stock is trading at $18.43, near its 52-week low, with a potential upside of over 138% to the new target. Enovis expects a 100 basis points headwind to 2027 adjusted EBITDA margins due to the acquisition, with margin improvement anticipated in 2028.
The FDA often approves drugs with postmarket safety studies, but many are delayed. Tavneos, a drug by Amgen, is one example with delays and reported liver damage cases. KFF Health News found hundreds of delayed studies, raising concerns about patient safety and wasted resources. The FDA defends its approach, citing legitimate reasons for delays. Companies like Pfizer and Amgen are working to complete their studies. The delays can leave patients and doctors uncertain about risks and benefits.
Conifer Management bought $40.6M of Group 1 Automotive (GPI) shares, while directors of Alpha Metallurgical (AMR), GameStop (GME), Tyson Foods (TSN), and Enovis (ENOV) made notable purchases. Silver Lake sold $47.2M of Dell (DELL) shares, with Dell trading near its 52-week high. Gratitude 2022 Trust sold $32M of AGNT shares, which are near a 52-week low.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ENOV (Enovis CORP). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent ENOV coverage spans financial news, insider activity and regulation.
Analyst downgrade suggests downside pressure on ENOV.
Delayed data could affect confidence in the ankle replacement product line.
Minor bullish indication.
Insider purchase may signal confidence from senior management, modestly supportive for the stock.
Potential bullish signal from insider buying at low levels.
AlphAI scores every news story that mentions ENOV with an AI model for sentiment and relevance, and aggregates insider trades from Enovis CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS reduced its price target for Enovis Corp (NYSE:ENOV) to $44 from $51, citing the impact of its recent acquisition and seasonality. The stock is trading at $18.43, near its 52-week low, with a potential upside of over 138% to the new target. Enovis expects a 100 basis points headwind to 2027 adjusted EBITDA margins due to the acquisition, with margin improvement anticipated in 2028.
2 min readThe FDA often approves drugs with postmarket safety studies, but many are delayed. Tavneos, a drug by Amgen, is one example with delays and reported liver damage cases. KFF Health News found hundreds of delayed studies, raising concerns about patient safety and wasted resources. The FDA defends its approach, citing legitimate reasons for delays. Companies like Pfizer and Amgen are working to complete their studies. The delays can leave patients and doctors uncertain about risks and benefits.
2 min readConifer Management bought $40.6M of Group 1 Automotive (GPI) shares, while directors of Alpha Metallurgical (AMR), GameStop (GME), Tyson Foods (TSN), and Enovis (ENOV) made notable purchases. Silver Lake sold $47.2M of Dell (DELL) shares, with Dell trading near its 52-week high. Gratitude 2022 Trust sold $32M of AGNT shares, which are near a 52-week low.
2 min readEngert Oliver (Chief Administrative Officer) purchased 2,660 shares of Enovis CORP (ENOV) at $18.80 on 2026-09-04.
1 min readEnovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.
3 min readEngert Oliver (Chief Administrative Officer) purchased 7,598 shares of Enovis CORP (ENOV) at an average of $19.74 ($19.46–$20.32, $0.15M total) across 2 trades over 2026-09-02 to 2026-09-03.
1 min readMcDonald Damien (Chief Executive Officer) purchased 13,035 shares of Enovis CORP (ENOV) at $19.15 ($0.25M total) on 2026-09-04.
1 min readEnovis (NYSE: ENOV) has made a binding offer to acquire eCential Robotics, a surgical robotics company. The deal is expected to close in Q4 2026, subject to regulatory approvals. eCential's Op.n® platform complements Enovis' technology portfolio, enhancing surgical precision and workflows. Both companies' CEOs expressed excitement about the strategic fit and future growth opportunities.
2 min readEnovis CORP (ENOV) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics , a Leading Developer of Enabling Technologies and Surgical Robotics ● Enhances Enovis’ enabling technology ecosystem to include robotic automation capabilities, empowering surgeons with a b
2 min readEnovis CORP (ENOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Enovis Announces Second Quarter 2026 Results • Second-quarter sales growth of 3% on a reported basis, 5% organic • Second-quarter Reconstructive sales growth of 8% on a reported basis, 6% organic • Reaffirmed full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and
6 min read
